Flatiron Health today announced its participation in the upcoming San Antonio Breast Cancer Symposium (SABCS), with four accepted abstracts for poster presentation. Additionally, the company will sponsor a session titled “How Holistic Real-World Evidence Generation Advances Breast Cancer Research.”
“We are deeply committed to advancing global oncology evidence generation, and it is an honor to present groundbreaking research at this year’s SABCS,” said Stephanie Reisinger, Senior Vice President and General Manager, Real-World Evidence, Flatiron Health. “For the past decade, Flatiron has led the way in providing innovative evidence solutions across the oncology landscape, helping clients unlock critical insights from discovery to commercialization by combining real-world data with cutting-edge science and technology.”
Highlights of Flatiron’s participation include:
- A poster presentation examining the use of real-world data to improve understanding of treatment and testing patterns in early breast cancer patients. It highlights gaps in genetic testing and the utilization of olaparib for eligible patients.
- A poster spotlight presentation showcasing the largest real-world comparative overall survival analysis of first-line CDK4/6 inhibitors plus aromatase inhibitor therapy in hormone receptor-positive, HER2-negative metastatic breast cancer, made possible by Flatiron’s expanded data offering.
- A speaking session hosted by Flatiron that explores how life science organizations can take a holistic approach to breast cancer research, featuring three customer case studies.
Flatiron invites attendees to schedule meetings at SABCS 2024 to learn more about their abstracts and events, including the panel discussion.
Follow Flatiron Health on Twitter and LinkedIn for the latest updates on #SABCS24.
Workshops & Panels
How Holistic Real-World Evidence Generation Advances Breast Cancer Research
Wednesday, December 11 at 3:30 PM CT
Speakers:
- Catherine Keane, RN, NP, Senior Clinical Director, Flatiron Health
Poster Discussions and Presentations
- Real-world demographics, clinical characteristics, and treatment patterns among US patients with HER2-negative early breast cancer and germline BRCA mutations since 2021
Partners: AstraZeneca, The Ohio State University Comprehensive Cancer Center
Presentation ID: PS2-03 - Clinical characteristics and treatment persistence in US patients with HR+/HER2-, node-positive early breast cancer treated with abemaciclib: Real-world study from first year after approval
Partners: Texas Oncology, Eli Lilly and Company, Moffitt Cancer Center
Presentation ID: P1-11-29 - Tolerability of First-Line treatment with ribociclib for metastatic breast cancer using two large US data sources
Partners: Dana-Farber Cancer Institute, University of Kansas, University of North Carolina, Novartis
Presentation ID: P3-10-14 - Comparative overall survival of CDK4/6 inhibitors plus aromatase inhibitors in HR+/HER2- metastatic breast cancer in the US real-world setting
Partners: Pfizer, University of San Francisco, MD Anderson, Dana-Farber Cancer Institute, and others
Presentation ID: P2-01-05
About Flatiron
Flatiron Health is a healthtech company focused on transforming oncology care through real-world evidence, machine learning, and AI. By creating a more connected oncology ecosystem, Flatiron turns patient experiences into actionable insights, advancing clinical trials and improving care for cancer patients. Flatiron is an independent affiliate of the Roche Group.